Short‐term anticoagulation after acute cardioversion of early‐onset atrial fibrillation

Controversy exists regarding anticoagulation management following acute cardioversion in patients with early‐onset (<48 hours) atrial fibrillation without class I guideline indication for long‐term oral anticoagulation (CHA2DS2‐VASc 0‐1).

[1]  G. Cervellin,et al.  Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience , 2019, Clinical and experimental emergency medicine.

[2]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[3]  P. Kirchhof,et al.  Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial , 2018, European heart journal.

[4]  G. Lip,et al.  Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA2DS2-VA Score Rather Than CHA2DS2-VASc? , 2018, Circulation.

[5]  M. Lamberts,et al.  Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients , 2017, Journal of the American Heart Association.

[6]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  G. Lip,et al.  Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.

[8]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  M. Chung,et al.  Incidence of Thromboembolic Complications Within 30 Days of Electrical Cardioversion Performed Within 48 Hours of Atrial Fibrillation Onset. , 2016, JACC. Clinical electrophysiology.

[10]  J. Hartikainen,et al.  Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). , 2016, The American journal of cardiology.

[11]  P. Cenni,et al.  Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk , 2016, Internal and Emergency Medicine.

[12]  T. Chao,et al.  Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.

[13]  A. Camm,et al.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.

[14]  G. Lip,et al.  Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. , 2014, The American journal of medicine.

[15]  J. Hartikainen,et al.  Time to cardioversion for acute atrial fibrillation and thromboembolic complications. , 2014, JAMA.

[16]  J. Hartikainen,et al.  Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. , 2013, Journal of the American College of Cardiology.

[17]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[18]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[19]  F. Loop,et al.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.